Carmat SA
PAR:ALCAR
Net Margin
Carmat SA
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| FR |
|
Carmat SA
PAR:ALCAR
|
51.2m EUR |
-965%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
223.1B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
183.3B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
150.3B USD |
12%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
139.2B USD |
13%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
108B USD |
13%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
52.9B EUR |
9%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
59.5B USD |
8%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
44.8B USD |
75%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
260.8B CNY |
33%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
35.7B USD |
23%
|
Carmat SA
Glance View
Carmat SA engages in the developing of implantable orthotropic and biocompatible artificial heart. The company is headquartered in Velizy-Villacoublay, Ile-De-France and currently employs 160 full-time employees. The company went IPO on 2010-07-07. The firm is developing an orthotopic and biocompatible artificial heart which works like a natural heart and which is hydraulically activated. The firm formed a network of partnerships with hospitals and various scientific companies, such as The Georges Pompidou European Hospital, The Marie Lannelongue Surgical Center, The Hospital Charles Nicolle of Rouen, Dedienne Sante, PaxiTech, Vignal Artru Industries, French Vessels and Blood Institute, Laboratoire de Recherche Biochirurgicale and others. As of December 31, 2011, a company MATRA DEFENSE held a 30.57% stake in the Company’s shareholdings.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Carmat SA's most recent financial statements, the company has Net Margin of -964.9%.
You don't have any saved screeners yet